Gordox

Gordox is an injectable solution that contains the active ingredient aprotinin. It is supplied in a sterile liquid form for intravenous administration. As a serine protease inhibitor, Gordox belongs to the antifibrinolytic therapeutic class and is marketed in the European Union as a prescription‑only medication.

Gordox is indicated for the prevention of excessive bleeding during certain surgical procedures, particularly cardiac surgery where control of fibrinolysis is critical.

- Reduces intra‑operative blood loss in coronary artery bypass grafting. - Helps maintain hemostasis during heart valve replacement. - Used as an adjunct in complex cardiac reconstructive surgeries. - May be employed when rapid clot stabilization is required. - Supports surgical teams in managing patients with high fibrinolytic activity.

Aprotinin can cause a range of adverse reactions, varying from mild to severe. Monitoring patients for signs of these effects is part of standard clinical practice.

Common: - Transient hypotension or hypertension. - Nausea, vomiting, or mild gastrointestinal discomfort. - Elevated serum creatinine levels indicating renal stress. - Mild allergic skin reactions such as rash or pruritus.

Serious: - Acute renal failure or significant decline in kidney function. - Severe hypersensitivity reactions, including anaphylaxis. - Thromboembolic events such as deep vein thrombosis or pulmonary embolism.

Before administering Gordox, clinicians should evaluate patient history and current clinical status to mitigate potential risks.

- Assess renal function; avoid use in patients with severe impairment. - Review any known hypersensitivity to aprotinin or related proteins. - Monitor coagulation parameters and platelet counts during treatment. - Use cautiously in patients with a history of cardiovascular disease. - Consider alternative antifibrinolytics if the patient is pregnant, as safety data are limited.

Gordox may interact with other medications that affect coagulation, renal function, or immune response. Awareness of these interactions helps optimize patient safety.

Avoid: - Concurrent use with other potent antifibrinolytic agents (e.g., tranexamic acid) without specialist guidance. - Simultaneous administration of nephrotoxic drugs such as aminoglycosides. - Combination with medications that significantly prolong bleeding time, like high‑dose aspirin or clopidogrel.

Use with caution: - Concomitant therapy with ACE inhibitors or ARBs, which may affect renal perfusion. - Co‑administration of immunosuppressants that could alter hypersensitivity risk. - Overlapping use with other serine protease inhibitors, requiring close monitoring of coagulation status.